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calcipotriol has been used in higher concentrations than calcitriol.
Long and Marks seem unaware of controlled studies showing that
calcipotriol ointment 50 pg/g is better than vehicle control.’ Now
that calcipotriol has been shown to compare favourably with
betamethasone 17-valerate, it may be possible to replace topical
corticosteroids with calcipotriol in many patients with psoriasis. We
should soon know how calcipotriol compares with dithranol: more
than 400 patients have entered a multicentre trial designed to
compare the efficacy and tolerability of the two agents.
Calcipotriol is by far the best studied vitamin KD analogue. The
results obtained in more than 3000 patients with psoriasis have
shown calcipotriol to be both effective and well-tolerated. It
represents a breakthrough in the topical treatment of psoriasis.
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Inhibition of hepatitis B virus by antisense
oligodeoxynucleotides
SIR,-Hepatitis B virus (HBV) infection is a major cause of
chronic liver disease and hepatocellular carcinoma world wide. 1
Although interferon alpha is effective in about one-third of
patients,2 other therapeutic strategies need to be explored.
We analysed the effect of antisense oligodeoxynucleotides on
HBV gene expression and replication. Transfection of human
hepatoma cells with HBV-DNA3 (control) results in the synthesis
and secretion of hepatitis B surface antigen (HBsAg) and hepatitis B
e antigen (HBeAg). Cotransfection of HBV-DNA with an
oligodeoxynucleotide of antisense polarity (ATC-40) completely
blocked HBsAg and HBeAg synthesis as well as HBV replication
(figure). The same oligodeoxynucleotide of sense polarity
(GAT-40) had no effect on viral antigen production or replication.
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Inhibition of viral antigen synthesis by HBV-specific antisense
oligodeoxynucleotide.
Detection of HBsAg (left) and HBeAg (right) in cell culture medium
after transfection of human hepatoma cells (HuH-7) with HBV-DNA
alone (&mdash;&mdash;&mdash;&mdash; control), HBV-DNA plus an antisense
oligodeoxynucleotide (w.w ATC-40), or HBV-DNA plus a sense
oligodeoxynucleotide (---A--- GAT-40). Analyses were completed with
commercially available radioimmunoassays (Centocor, Malvern, and
Abbott, Chicago, USA).
These data show that HBV-specific antisense
oligodeoxynucleotides can block viral gene expression and
replication. Inhibition of both human immunodeficiency virus
infection4 and lymphoma growths will have to await a clearer
definition of the role of antisense oligodeoxynucleotides, either
alone or in combination with other strategies.
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Cortisol response to corticotropin and
survival in septic shock
SIR,&mdash;Dr Rothwell and colleagues (March 9, p 582) show a poor
response to corticotropin in 13 patients with septic shock, all of
whom died. They state that "the cause of this apparent adrenal
impairment is unclear". We offer a possible explanation.
Cortisol plasma concentrations are usually raised in severe sepsis.
Interleukin-1 and tumour necrosis factor are lymphokines that play
an important part in endotoxin-mediated septic shock. It has been
suggested that these cytokines stimulate the ACTH-cortisol axis.l
The degree of rise in blood cortisol tends to reflect the severity of
sepsis. In Rothwell and colleagues’ report, total blood cortisol after
stimulation shows no significant difference between survivors and
non-survivors (1174 and 963 nmol/l, respectively). In our
experience, the stimulation from already stimulated adrenal glands
may result in a smaller difference between the basal concentration
and the 30-60-minute concentration than expected for the short
corticotropin stimulation test. In addition, we do not agree that a
trial of steroid replacement in severe sepsis with physiological doses
of cortisol might be of value because cortisol plasma concentrations
are already high in severe sepsis, as Rothwell et al recognise.
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SIR,-Dr Rothwell and colleagues state that "relative"
adrenocortical insufficiency may be observed often in patients with
septic shock. However, in our opinion, their data do not support this
conclusion.
The response of cortisol to corticotropin is known to be
dependent on baseline cortisol concentrations. In patients with high
basal concentrations, an attenuated response would be expected. 6
of the 13 reported patients with adrenocortical impairment had
strikingly increased baseline cortisol concentrations up to above
1500 nmol/1, which reflected the severity of the underlying disorder.
Lack of a cortisol response to corticotropin may be because the
pituitary-adrenal axis is already maximally stimulated in these
patients.
Rothwell et al do not comment on plasma ACTH concentrations
in their patients. Adrenocortical impairment of whatever origin in a
complex setting such as septic shock cannot be established without
complete biochemical investigation of the pituitary-adrenal axis.
Did patients with a poor response to corticotropin have higher
ACTH concentrations than patients with a "normal" response?
Since cortisol is bound to steroid binding globulin, did Rothwell et
al exclude the possibility that low total serum concentrations of
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cortisol in their patients were merely due to protein (steroid binding
globulin) loss in the interstitial space as is common in septic shock?
If protein loss were an important factor, free cortisol concentrations
could have been normal.
Rothwell et al also suggest a relation between a low cortisol
response to corticotropin and mortality. Was the poor cortisol
response reproducible? Was corticotropin given in the same way in
all patients (via a peripheral vein or a central line)? How was
mortality defined ? Furthermore, histopathological data on the
adrenal cortex are not given. Did patients have adrenalitis, adrenal
haemorrhage, adrenal necrosis, or normal adrenal histology? We
believe that further data are required before a final conclusion can be
drawn. We remain unconvinced that adrenocortical impairment is a
major difficulty in patients with septic shock.
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SIR,-Absolute adrenal insufficiency in overwhelming infection
is rare. The notion of absolute adrenal insufficiency as a cause of
refractory shock is gradually being replaced by the idea of relative
adrenal insufficiency.1 Dr Rothwell and colleagues noted a clear
stratification of stimulated cortisol release between survivors and
non-survivors, although basal cortisol concentrations were similar.
We have studied the interaction between the hypothalamic-
adrenal axis and phospholipase A2 in septic shock. Circulating
phospholipase A2 (PLA2) has been implicated in the pathogenesis
of cardiopulmonary changes in septic shock, and serum
concentrations of PLA2 correlate with outcome.2 Two
glucocorticoid-suppressible cytokines, tumour necrosis factor and
interleukin-1, are signals for PLA2 synthesis and extracellular
release.3 We measured ACTH, cortisol, and PLA2 concentrations
in a prospective study of ten episodes of septic shock.4 Serum
cortisol concentrations in individual patients varied up to four-fold,
although peak values were similar in survivors (mean [SD] 1397
[314] nmol/l, range 662-2480) and non-survivors (1232 [328]
nmol/1, range 450-2320). There was a complete discordance
between serum cortisol and ACTH concentrations in all patients,
irrespective of outcome. However, serum cortisol and PLA2 values
were concordant in all survivors (r > 069, p < 00001), but were
discordant in non-survivors (r = 0-26). These data, together with
those of Rothwell et al, suggest that adrenocortical responsiveness,
whether assessed by ACTH challenge or by concordance with
serum PLA2, is an important prognostic determinant of septic
shock.
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SIR,-Our experience is similar to that of Rothwell et al.
However, their report does not mention whether glucocorticoid
replacement was given to patients who were "adrenocortically
deficient"; if so, were any improvements seen, and did those
patients still have a poor final outcome? We found that replacement
was associated with both haemodynamic and clinical
improvement.’ Other workers have reported similar fmdings to
Ours.2,3
We have also shown that a blunted adrenocortical response to
corticotropin may take place in critically ill patients who do not have
established sepsis, and that treatment with steroids is associated
with an improved haemodynamic and clinical state.’ Our findings
suggest that adrenocortical deficiency is not specific to septicaemia
but may also occur in critically ill patients with other disorders
(Rothwell et al include one patient in their series with acute
pancreatitis who may have been in this category). The cause of this
effect is uncertain, but several inflammatory mediators such as
tumour necrosis factor are implicated, although these cytokines are
released in critically ill patients who are not septic.5 Adrenal failure
may be an under-recognised component of multiorgan failure in
patients who are critically ill, and should be sought actively.
Rothwell et al noted that all patients who failed to increase their
cortisol by at least 250 nmol/1 died. This group includes cases with a
wide range of basal cortisol concentrations. Although it is possible
that those with high baseline cortisol concentrations are "relatively
adrenocortically deficient", the more likely explanation is synthetic
hyperactivity. Such a response probably does not merit adjunctive
steroid therapy.
What does an impaired response to corticotropin mean? Is it a
marker of poor outlook, or does it imply that adrenal synthetic
function is impaired to a point where adverse effects result? Little
information is available on adrenal activity in critically ill patients.
Endogenous ACTH activity, delivery of ACTH to the adrenal
cortex, synthetic function in the gland, hormone release and plasma
binding, and cortisol breakdown are all factors that need to be
accounted for before concluding that a blunted response to
exogenous corticotropin implies adrenal exhaustion.
We agree that evidence exists to suggest that some crtitically ill
patients may merit adjunctive corticosteroid therapy as assessed by
the short ’Synacthen’ test, but such benefits may have been
obscured in large clinical trials in which high doses of steroid have
been given irrespective of endogenous adrenal function.
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Painful clitoral tumescence during
bromocriptine therapy
SIR,&mdash;Bromocriptine, a dopaminergic agonist, is used to
suppress lactation and prolactin secretion. We report a woman who
had clitoral tumescence during bromocriptine therapy.
A healthy woman, aged 28, was delivered of a normal male child
after an uneventful pregnancy. She was given paracetamol (500 mg
thrice daily on the day of delivery). Because she chose not to
breast-feed, she was given bromocriptine (2-5 mg twice daily
starting one day after delivery). Three days after treatment was
begun she had painful episodes of clitoral tumescence, lasting a few
minutes and arising about ten times a day when she was upright.
These episodes were not related to sexual arousal but an overall
increased libido was noticed. The patient temporarily discontinued
bromocriptine and had no futher episodes. However, she was again
given the drug for breast congestion and the episodes reappeared
1-2 h after dosing. Bromocriptine treatment was discontinued 19
days after delivery. The side-effects disappeared in the next few
days. The patient denied previous similar episodes. No other
side-effects were noted.
In an assessment by French workers of unexpected or toxic drug
reactions, the role of bromocriptine was regarded as convincing.l
We are not aware of other reports of clitoral tumescence as a
side-effect of this drug. As seen in our patient, increased libido can
be induced by levodopa2 and dopaminergic agonists,3 but not by
single-dose treatment.4 Dopaminergic agents induce erection, a
central nervous system effect mediated by dopamine, oxytocin, and
adrenocorticotropin hormone in animals and man.4-6
